Home › Research › Treatments
Determinants of Treatment Willingness and Willingness-to-Pay for Lecanemab in China
Arui Tan, Zuxing Wang, Étienne Aumont, Aonan Li, Xiaohong Qin, Xinxuan Yang, Wenqian Feng, Jianwei Yang et al.. Alzheimer Disease & Associated Disorders, 2025-09-16
Topic: Risk, prevention and care in population studies
Plain-language summary
W treat showed a strong direct association with W cost (0.99). W efficacy and W inconvenience indirectly influenced W treat through W cost (W efficacy -W inconvenience : 1.5, W inconvenience -W cost : 1.12, W cost -W treat : 0.99). Income (0.48) and effect (0.51) directly impacted W treat . Edu, edu.c, CDR, PSY, ZBI, and HS were indirectly correlated with W treat . W amount was directly associated with W treat (0.31), W cost (0.68), and W adverse (0.16). W efficacy and W inconvenience indirectly influenced W amount through W cost (W efficacy - W inconvenience : 1.5, W inconvenience -W cost : 1.12, W cost -W amount : 0.68). Network stability tests (CS >0.50) confirmed robustness. This study demonstrates that reducing payment barriers has a greater impact on real-world adoption of innovative therapies than clinical efficacy alone. Addressing financial constraints also enhances patients' willingness to pay. These findings provide evidence-based insights for developing patient-centered clinical decision pathways.
What this study adds
Evidence grade: Low
This study found that willingness to pay was strongly associated with willingness to treat, and that reducing payment barriers has a greater impact on real-world adoption of lecanemab than clinical efficacy alone. Addressing financial constraints also enhances patients' willingness to pay, informing patient-centred clinical decision pathways.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Tan, A., Wang, Z., Aumont, É., Li, A., Qin, X., Yang, X., et al. (2025). Determinants of Treatment Willingness and Willingness-to-Pay for Lecanemab in China. Alzheimer Disease & Associated Disorders. https://doi.org/10.1097/wad.0000000000000689
Vancouver
Tan A, Wang Z, Aumont É, Li A, Qin X, Yang X, et al. Determinants of Treatment Willingness and Willingness-to-Pay for Lecanemab in China. Alzheimer Disease & Associated Disorders. 2025. doi:10.1097/wad.0000000000000689. PMID: 40955711.
BibTeX
@article{tan2025-40955711,
author = {Tan, Arui and Wang, Zuxing and Aumont, Étienne and Li, Aonan and Qin, Xiaohong and Yang, Xinxuan and Feng, Wenqian and Yang, Jianwei and others},
title = {{Determinants of Treatment Willingness and Willingness-to-Pay for Lecanemab in China}},
journal = {Alzheimer Disease \& Associated Disorders},
year = {2025},
doi = {10.1097/wad.0000000000000689},
pmid = {40955711},
url = {https://doi.org/10.1097/wad.0000000000000689}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- W treat showed a strong direct association with W cost (0.99).
- W efficacy and W inconvenience indirectly influenced W treat through W cost (W efficacy -W inconvenience : 1.5, W inconvenience -W cost : 1.12, W cost -W treat : 0.99).
- Income (0.48) and effect (0.51) directly impacted W treat .
- Edu, edu.c, CDR, PSY, ZBI, and HS were indirectly correlated with W treat .
- W amount was directly associated with W treat (0.31), W cost (0.68), and W adverse (0.16).
Why it matters
This study found that willingness to pay was strongly associated with willingness to treat, and that reducing payment barriers has a greater impact on real-world adoption of lecanemab than clinical efficacy alone. Addressing financial constraints also enhances patients' willingness to pay, informing patient-centred clinical decision pathways.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 30/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer Disease & Associated Disorders) |
| Journal's citation record | 1 / 4 | Alzheimer Disease & Associated Disorders: journal h-index 131 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Jieying Li: h-index 21 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | McGill University: institution h-index 1,373 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40955711) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 30 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments from nearby years
Also in Treatments
196 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.